Pulmonary delivery of triptolide-loaded liposomes decorated with anti-carbonic anhydrase IX antibody for lung cancer therapy

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Lin, Congcong ^a   Wong, Blenda Chi Kwan ^a   Chen, Hubiao ^a   Bian, Zhaoxiang ^a   Zhang, Ge ^a   Zhang, Xue ^a   Kashif Riaz, Muhammad ^a   Tyagi, Deependra ^a   Lin, Ge ^b   Zhang, Yanbo ^c   Wang, Jinjin ^a   Lu, Aiping ^a   Yang, Zhijun ^a  

^a HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c THE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; CA9 PROTEIN, HUMAN; CARBONATE DEHYDRATASE IX; DITERPENE; EPOXIDE; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; LIPOSOME; MONOCLONAL ANTIBODY; PHENANTHRENE DERIVATIVE; TRIPTOLIDE; TUMOR ANTIGEN;

ANIMAL; BAGG ALBINO MOUSE; DRUG DELIVERY SYSTEM; HUMAN; IMMUNOLOGY; LUNG TUMOR; MALE; NON SMALL CELL LUNG CANCER; PROCEDURES; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; CARBONIC ANHYDRASE IX; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DITERPENES; DRUG DELIVERY SYSTEMS; EPOXY COMPOUNDS; HUMANS; LIPOSOMES; LUNG NEOPLASMS; MALE; MICE, INBRED BALB C; PHENANTHRENES;

EID: 85018167343     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-00957-4     Document Type: Article

References (50)

1. Siegel, R. L., Miller, K. D., Jemal, A. Cancer Statistics, 2015. Ca-Cancer J Clin 65, 5-29, doi:10.3322/caac.21254 (2015).
2. Garbuzenko, O. B., et al. Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides assuppressors of cellular resistance. Proceedings of the National Academy of Sciences of the United States of America 107, 10737-10742, doi:10.1073/pnas.1004604107 (2010).
3. Ramalingam, S. S., Owonikoko, T. K., Khuri, F. R. Lung Cancer: New Biological Insights and Recent Therapeutic Advances. Ca-Cancer J Clin 61, 91-112, doi:10.3322/caac.20102 (2011).
4. Mura, S., Nicolas, J., Couvreur, P. Stimuli-responsive nanocarriers for drug delivery. Nature materials 12, 991-1003, doi:10.1038/NMAT3776 (2013).
5. Murakami, M., et al. Improving Drug Potency and Efficacy by Nanocarrier-Mediated Subcellular Targeting. Sci Transl Med 3, doi:ARTN 64ra210.1126/scitranslmed.3001385 (2011).
6. Allen, T. M. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2, 750-763, doi:10.1038/nrc903 (2002).
7. Chiche, J., et al. Hypoxia-Inducible Carbonic Anhydrase IX and XII Promote Tumor Cell Growth by Counteracting Acidosis throughthe Regulation of the Intracellular pH. Cancer research 69, 358-368, doi:10.1158/0008-5472.CAN-08-2470 (2009).
8. Vermylen, P., et al. Carbonic anhydrase IX antigen differentiates between preneoplastic malignant lesions in non-small cell lungcarcinoma. European Respiratory Journal 14, 806-811, doi:10.1034/j.1399-3003.1999.14d14.x (1999).
9. Swinson, D. E. B., et al. Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poorprognosis in non-small-cell lung cancer. J Clin Oncol 21, 473-482, doi:10.1200/Jco.2003.11.132 (2003).
10. Le, Q. T., et al. An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers.Clinical Cancer Research 12, 1507-1514, doi:10.1158/1078-0432.CCR-05-2049 (2006).
11. Liao, S. Y., Aurelio, O. N., Jan, K., Zavada, J., Stanbridge, E. J. Identification of the MN/CA9 protein as a reliable diagnosticbiomarker of clear cell carcinoma of the kidney. Cancer research 57, 2827-2831 (1997).
12. Saarnio, J., et al. Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation. Am J Pathol 153, 279-285, doi:10.1016/S0002-9440(10)65569-1(1998).
13. Wykoff, C. C., et al. Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of thebreast. Am J Pathol 158, 1011-1019, doi:10.1016/S0002-9440(10)64048-5 (2001).
14. Simi, L., et al. Quantitative analysis of carbonic anhydrase IX mRNA in human non-small cell lung cancer. Lung Cancer 52, 59-66, doi:10.1016/j.lungcan.2005.11.017 (2006).
15. Pastorekova, S., et al. Carbonic anhydrase IX, MN/CA IX: Analysis of stomach complementary DNA sequence and expression inhuman and rat alimentary tracts. Gastroenterology 112, 398-408, doi:10.1053/gast.1997.v112.pm9024293 (1997).
16. De Simone, G., Supuran, C. T. Carbonic anhydrase IX: Biochemical and crystallographic characterization of a novel antitumortarget. Bba-Proteins Proteom 1804, 404-409, doi:10.1016/j.bbapap.2009.07.027 (2010).
17. Alterio, V., Di Fiore, A., D'Ambrosio, K., Supuran, C. T., De Simone, G. Multiple binding modes of inhibitors to carbonicanhydrases: How to design specific drugs targeting 15 different isoforms Chem Rev 112, 4421-4468, doi:10.1021/cr200176r (2012).
18. ClinicalTrials Database: NCT02215850. https://clinicaltrials.gov.
19. Mahon, B. P., Pinard, M. A., McKenna, R. Targeting carbonic anhydrase IX activity and expression. Molecules 20, 2323-2348, doi:10.3390/molecules20022323 (2015).
20. Siebels, M., et al. A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX(A (R))) and interferon-alpha-2a inmetastatic renal cell carcinoma patients. World J Urol 29, 121-126, doi:10.1007/s00345-010-0570-2 (2011).
21. Belldegrun, A. S., et al. ARISER: A randomized double blind phase III study to evaluate adjuvant cG250 treatment versus placebo inpatients with high-risk ccRCC-Results and implications for adjuvant clinical trials. J Clin Oncol 31 (2013).
22. Zatovicova, M., et al. Ectodomain shedding of the hypoxia-induced carbonic anhydrase IX is a metalloprotease-dependent processregulated by TACE/ADAM17. Br J Cancer 93, 1267-1276, doi:10.1038/sj.bjc.6602861 (2005).
23. Li, Y. Q., Shen, B. H., Kim, J., Raz, D. Triptolide inhibits Wnt signaling due to DNA methylation alteration that is determined bydynamic histone 3 K79 lysine methylation in NSCLC. Cancer research 75, doi:10.1158/1538-7445.AM2015-4777 (2015).
24. Li, X. F., et al. Triptolide reduces proliferation and enhances apoptosis of human non-small cell lung cancer cells through PTEN bytargeting miR-21. Mol Med Rep 13, 2763-2768, doi:10.3892/mmr.2016.4844 (2016).
25. Reno, T. A., Kim, J. Y., Raz, D. J. Triptolide Inhibits Lung Cancer Cell Migration, Invasion, Metastasis. Annals Of ThoracicSurgery 100, 1817-1825, doi:10.1016/j.athoracsur.2015.05.074 (2015).
26. Zhou, Z. L., Yang, Y. X., Ding, J., Li, Y. C., Miao, Z. H. Triptolide: Structural modifications, structure-activity relationships, bioactivities, clinical development and mechanisms. Nat Prod Rep 29, 457-475, doi:10.1039/c2np00088a (2012).
27. Frese, S., et al. PG490-mediated sensitization of lung cancer cells to Apo2L/TRAIL-induced apoptosis requires activation of ERK2.Oncogene 22, 5427-5435, doi:10.1038/sj.onc.1206842 (2003).
28. Lee, K. Y., Park, J. S., Jee, Y. K., Rosen, G. D. Triptolide sensitizes lung cancer cells to TNF-related apoptosis-inducing ligand(TRAIL)-induced apoptosis by inhibition of NF-kappa B activation. Experimental And Molecular Medicine 34, 462-468 (2002).
29. Patil, S., et al. Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, Efficacy in HumanColon Adenocarcinoma and Ovarian Cancer Xenografts. Journal of medicinal chemistry 58, 9334-9344, doi:10.1021/acs.jmedchem.5b01329 (2015).
30. Manjappa, A. S., et al. Antibody derivatization and conjugation strategies: Application in preparation of stealth immunoliposome totarget chemotherapeutics to tumor. J Control Release 150, 2-22, doi:10.1016/j.jconrel.2010.11.002 (2011).
31. Hutterer, K. M., et al. Monoclonal antibody disulfide reduction during manufacturing: Untangling process effects from producteffects. mAbs 5, 608-613, doi:10.4161/mabs.24725 (2013).
32. Mahmoud, W., et al. Advanced procedures for labeling of antibodies with quantum dots. Analytical biochemistry 416, 180-185, doi:10.1016/j.ab.2011.05.018 (2011).
33. Moles, E., et al. Immunoliposome-mediated drug delivery to Plasmodium-infected and non-infected red blood cells as a dualtherapeutic/prophylactic antimalarial strategy. J Control Release 210, 217-229, doi:10.1016/j.jconrel.2015.05.284 (2015).
34. McIntyre, A., et al. Carbonic Anhydrase IX Promotes Tumor Growth and Necrosis In Vivo and Inhibition Enhances Anti-VEGFTherapy. Clinical Cancer Research 18, 3100-3111, doi:10.1158/1078-0432.CCR-11-1877 (2012).
35. McDonald, P. C., Winum, J. Y., Supuran, C. T., Dedhar, S. Recent Developments in Targeting Carbonic Anhydrase IX for CancerTherapeutics. Oncotarget 3, 84-97 (2012).
36. Mehta, G., Hsiao, A. Y., Ingram, M., Luker, G. D., Takayama, S. Opportunities and challenges for use of tumor spheroids as modelsto test drug delivery and efficacy. J Control Release 164, 192-204, doi:10.1016/j.jconrel.2012.04.045 (2012).
37. Fidler, I. J., et al. Modulation Of Tumor-Cell Response To Chemotherapy by the Organ Environment. Cancer Metast Rev 13, 209-222, doi:10.1007/Bf00689637 (1994).
38. Wilmanns, C., Fan, D., Obrian, C. A., Bucana, C. D., Fidler, I. J. Orthotopic And Ectopic Organ Environments DifferentiallyInfluence the Sensitivity Of Murine Colon-Carcinoma Cells To Doxorubicin And 5-Fluorouracil. Int J Cancer 52, 98-104, doi:10.1002/ijc.2910520118 (1992).
39. Onn, A., et al. Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice.Clinical Cancer Research 9, 5532-5539 (2003).
40. Luo, T., et al. PEGylation of paclitaxel largely improves its safety and anti-tumor efficacy following pulmonary delivery in a mousemodel of lung carcinoma. J Control Release 239, 62-71, doi:10.1016/j.jconrel.2016.08.008 (2016).
41. Owens, D. E., Peppas, N. A. Opsonization, biodistribution, pharmacokinetics of polymeric nanoparticles. Int J Pharm 307, 93-102, doi:10.1016/j.ijpharm.2005.10.010 (2006).
42. Chaudhari, K. R., et al. Opsonization, Biodistribution, Cellular Uptake and Apoptosis Study of PEGylated PBCA Nanoparticle asPotential Drug Delivery Carrier. Pharmaceutical research 29, 53-68, doi:10.1007/s11095-011-0510-x (2012).
43. Zhang, Z. R., et al. The targeting of 14-succinate triptolide-lysozyme conjugate to proximal renal tubular epithelial cells. Biomaterials30, 1372-1381, doi:10.1016/j.biomaterials.2008.11.035 (2009).
44. Pons, M., Foradada, M., Estelrich, J. Liposomes Obtained by the Ethanol Injection Method. Int J Pharm 95, 51-56, doi:10.1016/0378-5173(93)90389-W (1993).
45. Wong, B. C. K., et al. Carbonic anhydrase IX-directed immunoliposomes for targeted drug delivery to human lung cancer cells invitro. Drug Des Dev Ther 8, 993-1001, doi:10.2147/Dddt.S63235 (2014).
46. Iden, D. L., Allen, T. M. In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniqueswith those made by a new post-insertion approach. Bba-Biomembranes 1513, 207-216, doi:10.1016/S0005-2736(01)00357-1(2001).
47. Urban, P., Estelrich, J., Cortes, A., Fernandez-Busquets, X. A nanovector with complete discrimination for targeted delivery toPlasmodium falciparum-infected versus non-infected red blood cells in vitro. J Control Release 151, 202-211, doi:10.1016/j.jconrel.2011.01.001 (2011).
48. Wei, T., et al. Functionalized Nanoscale Micelles Improve Drug Delivery for Cancer Therapy in Vitro and in Vivo. Nano Lett 13, 2528-2534, doi:10.1021/nl400586t (2013).
49. Liu, Y. Y., et al. Paclitaxel loaded liposomes decorated with a multifunctional tandem peptide for glioma targeting. Biomaterials 35, 4835-4847, doi:10.1016/j.biomaterials.2014.02.031 (2014).
50. Fidler, J. M., An, J. H., Carter, B. Z., Andreeff, M. Preclinical antileukemic activity, toxicology, toxicokinetics and formulationdevelopment of triptolide derivative MRx102. Cancer Chemoth Pharm 73, 961-974, doi:10.1007/s00280-014-2428-6 (2014).